このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Eggshell-Derived Hydroxyapatite With Platelet-Rich Fibrin for Bone Regeneration After Jaw Cyst Removal

2026年11月5日 更新者:Ahmed Nasser Ali Mabkhout

Evaluation of Eggshell-Derived Hydroxyapatite Enhanced With Platelet-Rich Fibrin for Alveolar Bone Regeneration Following Cyst Enucleation

This clinical study aims to evaluate bone healing after the surgical removal of jaw cysts using a bone graft material made from chicken eggshells, with or without platelet-rich fibrin (PRF), a substance prepared from the patient's own blood.

Removal of a jaw cyst can leave an empty space in the surrounding bone. Although this space may heal naturally, bone regeneration can take several months. Hydroxyapatite is a bone-like mineral that may support new bone formation. Combining it with PRF may further improve healing.

This prospective, controlled clinical study is being conducted in Sana'a, Yemen. Participants undergo surgical removal of jaw cysts and receive one of the treatment approaches included in the study. The researchers compare bone healing between treatment groups using clinical examinations and dental imaging, including cone-beam computed tomography (CBCT).

Participants are followed for up to six months after surgery. The study evaluates bone regeneration, postoperative pain, wound healing, and possible complications.

The researchers aim to determine whether eggshell-derived hydroxyapatite combined with PRF improves bone regeneration compared with the other treatments being investigated.

調査の概要

詳細な説明

This prospective, controlled, non-randomized interventional clinical study evaluates the clinical and radiographic outcomes of eggshell-derived hydroxyapatite (HA) enhanced with autologous platelet-rich fibrin (PRF) for alveolar bone regeneration following the enucleation of odontogenic jaw cysts.

The study is conducted in Sana'a, Yemen, among adult patients requiring surgical enucleation of jaw cysts associated with residual bone defects.

The investigational bone graft material is synthesized from processed chicken eggshells using a chemical preparation method involving phosphoric acid. The resulting calcium phosphate material undergoes physicochemical characterization and is prepared for clinical application under controlled aseptic conditions.

The clinical study includes three treatment groups. Participants are assigned using a repeating A-B-C allocation sequence rather than random assignment. The study evaluates eggshell-derived HA combined with autologous PRF against the other treatment approaches defined in the clinical protocol.

When PRF is used, venous blood is collected from the participant and centrifuged without anticoagulants to obtain a fibrin-rich preparation. The PRF is combined with the prepared HA material and applied to the residual bone defect after cyst enucleation.

Participants undergo standardized surgical management and postoperative clinical assessment. Clinical evaluations include wound healing, postoperative pain, swelling, infection, wound dehiscence, and other treatment-related complications.

Radiographic assessments include panoramic radiography and cone-beam computed tomography (CBCT). Bone regeneration is evaluated through changes in residual defect dimensions and radiographic healing during postoperative follow-up, including assessments at three and six months.

The primary objective is to compare radiographic bone regeneration following cyst enucleation among the treatment groups. Secondary objectives include evaluating soft tissue healing, postoperative discomfort, and treatment-related complications.

The study hypothesis is that eggshell-derived HA combined with autologous PRF may provide improved bone regeneration compared with the other treatment approaches. The investigation is intended to generate clinical evidence regarding the regenerative performance and safety of the locally prepared bone graft material.

研究の種類

介入

入学 (推定)

30

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Sanaa、イエメン
        • 募集
        • Faculty of Dentistry, Sana'a University
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~60年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

**Inclusion Criteria:**

  • Adult patients aged 18 to 60 years.
  • Patients diagnosed with odontogenic jaw cysts requiring surgical enucleation.
  • Patients with residual jawbone defects measuring at least 1.5 cm following cyst enucleation.
  • Patients in good general health or with medically controlled systemic conditions.
  • Patients who provide informed consent to participate in the clinical study and agree to scheduled postoperative follow-up examinations.

**Exclusion Criteria:**

  • Patients with an active infection at the surgical site.
  • Patients with a history of radiation therapy or bisphosphonate use.
  • Patients with systemic bone diseases or immunosuppression.
  • Pregnant or lactating women.
  • Patients with known allergies or intolerance to any materials used in the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group A: Eggshell-Derived HA + PRF

Following surgical enucleation of the odontogenic jaw cyst, the residual bone defect is filled with locally prepared eggshell-derived hydroxyapatite combined with autologous platelet-rich fibrin (PRF). The PRF is obtained from the patient's venous blood by centrifugation without anticoagulants. The combined graft is placed into the bone cavity before surgical wound closure.

アクティブコンパレータ:Group B: Eggshell-Derived HA Alone

Following surgical enucleation of the odontogenic jaw cyst, the residual bone defect is filled with eggshell-derived hydroxyapatite without platelet-rich fibrin. The graft is placed directly into the bone cavity before surgical wound closure.

介入なし:Group C: Spontaneous Bone Healing

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Alveolar Bone Defect Dimensions Following Cyst Enucleation
時間枠:Baseline and 3 and 6 months after surgery

Radiographic bone regeneration is assessed by measuring changes in the vertical and horizontal dimensions of the residual bone defect in millimeters using cone-beam computed tomography (CBCT). Measurements obtained at baseline are compared with those at 3 and 6 months after surgery to evaluate bone defect reduction among the treatment groups.

Baseline and 3 and 6 months after surgery
Change in Radiographic Density Within the Healing Bone Defect
時間枠:Baseline and 3 and 6 months after surgery

Changes in radiographic density within the bone defect are evaluated using CBCT image gray values obtained from a defined region of interest. Measurements are compared between baseline and follow-up examinations at 3 and 6 months, using a consistent imaging and measurement protocol. Gray values are reported as relative radiographic measurements rather than calibrated Hounsfield units.

Baseline and 3 and 6 months after surgery

二次結果の測定

結果測定
メジャーの説明
時間枠
Postoperative Pain Intensity
時間枠:1 week, 1 month, 3 months, and 6 months after surgery

Postoperative pain is assessed using a patient-reported visual analog scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores are recorded during postoperative follow-up visits and compared among the treatment groups.

1 week, 1 month, 3 months, and 6 months after surgery
Clinical Soft Tissue Healing
時間枠:1 week, 1 month, 3 months, and 6 months after surgery

Healing of the surgical site is assessed clinically by examining mucosal wound closure and recording the presence or absence of swelling and wound dehiscence during postoperative follow-up visits.

1 week, 1 month, 3 months, and 6 months after surgery
Incidence of Postoperative Complications
時間枠:From surgery through 6 months of postoperative follow-up

The number of participants experiencing postoperative complications, including surgical-site infection, wound dehiscence, or other documented procedure-related complications, is recorded and compared among the treatment groups.

From surgery through 6 months of postoperative follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年9月14日

一次修了 (推定)

2027年12月30日

研究の完了 (推定)

2027年12月30日

試験登録日

最初に提出

2026年11月5日

QC基準を満たした最初の提出物

2026年11月5日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data (IPD) will not be shared with external researchers. Participant-level clinical and radiographic data will be kept confidential in accordance with the approved study protocol, institutional ethical requirements, and applicable data protection regulations. Aggregated and anonymized study results may be reported in scientific publications.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する